SLV308 for Treatment of Patients With Early Parkinson's Disease
Public ClinicalTrials.gov record NCT00269516. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Study identification
- NCT ID
- NCT00269516
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 468 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2006
- Primary completion
- Nov 30, 2007
- Completion
- Nov 30, 2007
- Last update posted
- Aug 28, 2008
2006 – 2007
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 284 | Huntsville | Alabama | — | — |
| Site 274 | Little Rock | Arkansas | — | — |
| Site 283 | Fountain Valley | California | — | — |
| Site 277 | La Jolla | California | — | — |
| Site 271 | San Francisco | California | — | — |
| Site 279 | Fort Lauderdale | Florida | — | — |
| Site 293 | Gainsville | Florida | — | — |
| Site 282 | Port Charlotte | Florida | — | — |
| Site 285 | Sunrise | Florida | — | — |
| Site 273 | Tampa | Florida | — | — |
| Site 290 | Chicago | Illinois | — | — |
| Site 280 | Kansas City | Kansas | — | — |
| Site 292 | Bingham Farms | Michigan | — | — |
| Site 275 | Traverse City | Michigan | — | — |
| Site 276 | St Louis | Missouri | — | — |
| Site 287 | St Louis | Missouri | — | — |
| Site 278 | Las Vegas | Nevada | — | — |
| Site 286 | Rochester | New York | — | — |
| Site 288 | Ashville | North Carolina | — | — |
| Site 289 | Charlotte | North Carolina | — | — |
| Site 294 | Toledo | Ohio | — | — |
| Site 281 | Pittsburgh | Pennsylvania | — | — |
| Site 291 | Warwick | Rhode Island | — | — |
| Site 272 | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00269516, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2008 · Synced Sep 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00269516 live on ClinicalTrials.gov.